

**In the Claims:**

1. (Original) A bivalent or multivalent antibody characterized by the following features:
  - (a) it is capable of suppressing an immune reaction;
  - (b) it is devoid of constant antibody regions; and
  - (c) it binds an epitope on the CD3 complex of the T-cell receptor.
2. (Original) The antibody of claim 1 that is a diabody.
3. (Original) The antibody of claim 1 that comprises two scFv antibodies linked by a peptide linker.
4. (Original) The antibody of claim 1 that is a single chain diabody.
5. (Currently Amended) The antibody according to ~~any one of claims 1 to 4~~ claim 1, wherein the its variable V<sub>H</sub> and V<sub>L</sub> domains are connected via the peptide linker SAKTTP or SAKTTPKLGG.
6. (Currently Amended) The antibody according to ~~any one of claims 1 to 5~~ claim 1, wherein the its variable domains correspond to the variable domains of the an antibody produced by the hybridoma of ATCC deposit number CRL 8001.
7. (Currently Amended) The antibody according to claim 6, wherein a cysteine at position H100A (~~Kabat numbering system~~) has been exchanged for another amino acid.
8. (Original) The antibody according to claim 7, wherein the cysteine has been exchanged for a serine.

9. (Currently Amended) A polynucleotide, which encodes an antibody ~~of any one of claims 1 to 8~~ according to claim 1.

10. (Original) An expression vector comprising the polynucleotide of claim 9.

11. (Original) The expression vector of claim 10, which is pSKK3-scFv\_6-anti-CD3 (DSM 15137).

12. (Original) A host cell containing the expression vector of claim 10 or 11.

13. (Currently Amended) A pharmaceutical composition ~~containing~~ comprising the antibody of ~~any one of claims 1 to 8~~ claim 1, the polynucleotide of claim 9, or the expression vector of claim 10 ~~or 11~~.

14. (Currently Amended) ~~Use of an antibody which is characterized by the following features:~~  
~~(a) it is capable of suppressing an immune reaction;~~  
~~(b) it is devoid of constant antibody regions; and~~  
~~(c) it binds an epitope on the CD3 complex of the T-cell receptor; or the polynucleotide of claim 9 or the expression vector of claim 10 or 11 for the preparation of a pharmaceutical composition~~ A method for immunotherapy comprising the step of administering to a subject the pharmaceutical composition according to claim 13.

15. (Currently Amended) ~~Use according to claim 14, wherein the antibody is~~ A method for immunotherapy comprising the step of administering to a subject a pharmaceutical composition comprising the antibody of any one of claims 1 to 8 claim 1.

16. (Currently Amended) Use The method according to claim 14 ~~or 15~~, wherein said immunotherapy is a therapy against acute transplant rejections.

17. (Currently Amended) ~~Use of~~ A method for gene therapy comprising the step of administering to a subject a pharmaceutical composition comprising the polynucleotide of claim 9 or the expression vector of claim 10 or 11 for the preparation of a pharmaceutical composition for gene therapy.